Zymeworks Common Stock Stock In The News
| ZYME Stock | USD 13.06 0.08 0.61% |
Our overall analysis of Zymeworks Common's news coverage and content from conventional and social sources shows investors' bearish mood towards Zymeworks Common Stock. The specific impact of Zymeworks Common news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Zymeworks Common's overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Zymeworks Common headlines in addition to utilizing other, more conventional financial analysis modules. Check out Zymeworks Common Backtesting and Zymeworks Common Hype Analysis.
Zymeworks |
Zymeworks Common Today Top News and Investor Outlook
Zymeworks Common Stock Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Zymeworks and other traded companies coverage with news coverage. We help investors stay connected with Zymeworks headlines for the 11th of December 2024 to make an informed investment decision based on correlating the impacts of news items on Zymeworks Stock performance. Please note that trading solely based on the Zymeworks Common Stock hype is not for everyone as timely availability and quick action are needed to avoid losses.
Zymeworks Common stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Zymeworks earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Zymeworks Common that are available to investors today. That information is available publicly through Zymeworks media outlets and privately through word of mouth or via Zymeworks internal channels. However, regardless of the origin, that massive amount of Zymeworks data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Zymeworks Common news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Zymeworks Common relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Zymeworks Common's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Zymeworks Common alpha.
Zymeworks Largest EPS Surprises
Earnings surprises can significantly impact Zymeworks Common's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-01 | 2024-06-30 | -0.32 | -0.27 | 0.05 | 15 | ||
2023-11-07 | 2023-09-30 | -0.47 | -0.41 | 0.06 | 12 | ||
2018-11-06 | 2018-09-30 | -0.67 | -0.59 | 0.08 | 11 | ||
2020-08-05 | 2020-06-30 | -0.86 | -0.77 | 0.09 | 10 | ||
2017-11-08 | 2017-09-30 | -0.54 | -0.64 | -0.1 | 18 | ||
2019-05-02 | 2019-03-31 | -0.54 | -0.43 | 0.11 | 20 |
Zymeworks Common Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Zymeworks Common Stock Stock. Current markets are slightly bearish. About 55% of major world exchanges and indexes are down. See today's market update for more information.
9th of December 2024
Zymeworks Stock Price Down 7.2 percent Time to Sell at thelincolnianonline.com
21st of November 2024
FDA Grants U.S. Approval of Ziihera for the Treatment of Adults with Previously Treated, U... at globenewswire.com
20th of November 2024
Acquisition by Kenneth Galbraith of 215000 shares of Zymeworks Common at 8.0 subject to Ru... at Kenneth Galbraith
18th of November 2024
CAR T-Cell Therapy Market to Surpass Valuation of USD 106.06 Billion by 2031 SkyQuest Tech... at finance.yahoo.com
8th of November 2024
Zymeworks Upgraded at Leerink Partnrs at thelincolnianonline.com
5th of November 2024
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Fola... at finance.yahoo.com
1st of November 2024
Zymeworks Inc. Analysts Are Reducing Their Forecasts For Next Year at finance.yahoo.com
31st of October 2024
Zymeworks Inc. Reports Q3 Loss, Lags Revenue Estimates at zacks.com
24th of September 2024
Epigenetics Market to Witness 14.8 percent CAGR by 2031 SkyQuest Technology at finance.yahoo.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Zymeworks Common in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Zymeworks Common's short interest history, or implied volatility extrapolated from Zymeworks Common options trading.
Check out Zymeworks Common Backtesting and Zymeworks Common Hype Analysis. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zymeworks Common. If investors know Zymeworks will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zymeworks Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.49) | Revenue Per Share 0.831 | Quarterly Revenue Growth (0.03) | Return On Assets (0.15) | Return On Equity (0.29) |
The market value of Zymeworks Common Stock is measured differently than its book value, which is the value of Zymeworks that is recorded on the company's balance sheet. Investors also form their own opinion of Zymeworks Common's value that differs from its market value or its book value, called intrinsic value, which is Zymeworks Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zymeworks Common's market value can be influenced by many factors that don't directly affect Zymeworks Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zymeworks Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zymeworks Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zymeworks Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.